Profile Picture
Rewards
  • All
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
    • Travel
    • Hotels
    • Real Estate
    • My Bing
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Politics
  • Business

Trending on Bing

Biden impeachment resolution
Warns Swift of popularity fall
CN balloon seen in Taiwan
'Pink Friday 2' released
‘J.D.'s Revenge' star dies
To exit 'FBI: International'
Whitaker's ex-wife dies
Copyright infringement suit
Wife had brain surgery
Rahm joining LIV Golf
Dating Benny Blanco?
'One Life to Live' star dies
JP pledges more aid to UKR
Finalize 2-year, $12M deal
Pacers advance to finals
Spotify CFO to step down
Calif. budget deficit swells
10M signed up in December
Calls for Iger to be fired
Scorsese to be honored
Israel, US postwar visions
Levi Strauss' new CEO
Journalist killed by Israel?
Fires 35 organized workers
To run for Santos' seat
Returns after cardiac arrest
Appeals immunity ruling
Apologizes for 9/11 remarks
The Game Awards 2023
'Peach Fuzz' color of the yr
Arrested on cocaine charges
Unfair labor practice strike
Employee charged w/ stealing
Indicted on nine tax charges
Mets sign López
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent
5,160 results
Proactiveinvestors29d
AstraZeneca faces lawsuits in High Court over ‘defective’ Covid-19 vaccine
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced ...
The Motley Fool21d
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
AstraZeneca is making another go at developing a medicine like Ozempic. The U.K. pharma giant purchased licensing rights to a candidate in early-stage clinical trials. But that drug will need ...
The Financial Times29d
AstraZeneca signs deal for oral obesity drug and lifts profit outlook
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. AstraZeneca is to enter the race for a weight loss pill, working on a next-generation class of drugs that ...
Reuters24d
AstraZeneca's Imfinzi plus chemoradiotherapy fail main goal of late stage trial
Nov 14 (Reuters) - Drugmaker AstraZeneca (AZN.L) said on Tuesday its cancer drug Imfinzi given along with chemoradiotherapy (CRT) failed to meet its main goal in a late-stage trial to treat ...
Hosted on MSN29d
AstraZeneca CEO Pascal Soriot: Treatment of cancer in the last few years has been 'remarkable'
AstraZeneca CEO Pascal Soriot discusses Q3 earnings, oncology revenue, gene therapy treatments, what's to come for the company and the U.S. supply chain. Donald Trump Being Kicked off 2024 Ballot ...
MarketWatch29d
AstraZeneca Shares Rise After Guidance Increase
Shares of AstraZeneca rose as much as 4.2% in early trade after the company raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines after beating ...
Morningstar4d
AstraZeneca PLC ADR AZN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Investing17d
AstraZeneca: Leading bank tells us why the stock is a core holding
Proactive Investors - Barclays (LON:BARC) Capital has issued an optimistic assessment of AstraZeneca PLC (LON:AZN)'s shares, recommending an 'overweight' position with a target price of £135, a ...
Proactive Investors28d
AstraZeneca faces lawsuits in High Court over ‘defective’ Covid-19 vaccine
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
© 2023 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices